Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

1.1K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
1.1K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

8.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
8.4K
Hormones of the Pituitary Gland01:27

Hormones of the Pituitary Gland

15.1K
The small, pea-sized pituitary gland is located at the base of the brain. It is crucial in regulating various bodily functions, from growth to reproduction. The gland is divided into the anterior lobe and the posterior lobe. The secretory cell clusters in the pars distalis of the anterior pituitary lobe are controlled by hypothalamic regulators and synthesize six primary hormones.
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
15.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alexander von Humboldt and the little women of Loja.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society·2026
Same author

Diazoxide choline extended-release (DCCR) use in Prader-Willi syndrome: patient selection, dosing, and management.

Journal of the Endocrine Society·2026
Same author

Diazoxide Choline Extended-release Tablets in Prader-Willi Syndrome: A Randomized, Double-blind, Withdrawal Period Study.

The Journal of clinical endocrinology and metabolism·2026
Same author

Measurement of 11-Oxo-androgens, A Novel Biomarker, in Females with Clinical Signs of Premature Adrenarche

Journal of clinical research in pediatric endocrinology·2025
Same author

Plasma from type 1 diabetes patients promotes pro-atherogenic cholesterol transport in human macrophages.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2024
Same author

24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency.

The Journal of clinical endocrinology and metabolism·2013

Related Experiment Video

Updated: Mar 28, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
11:17

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

17.2K

Long-Acting Growth Hormone: An Update.

Paul H Saenger, Jorge Mejia-Corletto

    Endocrine Development
    |December 20, 2015
    PubMed
    Summary

    Long-acting growth hormone formulations aim to improve treatment adherence and outcomes for patients requiring growth hormone therapy. These new options reduce the burden of daily injections, enhancing patient and caregiver acceptance.

    Area of Science:

    • Pediatric Endocrinology
    • Pharmacology
    • Biotechnology

    Background:

    • Recombinant human growth hormone (rhGH) has been a vital treatment since 1985.
    • Current daily rhGH injections present challenges in adherence and convenience for pediatric patients.
    • Nonadherence to daily injections can lead to suboptimal clinical outcomes.

    Purpose of the Study:

    • To review advancements in long-acting growth hormone formulations.
    • To explore strategies for improving patient adherence and therapeutic outcomes.
    • To highlight the development of sustained-release rhGH preparations.

    Main Methods:

    • Review of current and recent research on long-acting rhGH formulations.
    • Analysis of strategies to reduce injection frequency.

    More Related Videos

    Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
    03:22

    Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

    Published on: January 27, 2018

    15.8K
    Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
    06:24

    Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

    Published on: January 10, 2025

    1.7K

    Related Experiment Videos

    Last Updated: Mar 28, 2026

    Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
    11:17

    Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

    Published on: January 7, 2016

    17.2K
    Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
    03:22

    Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

    Published on: January 27, 2018

    15.8K
    Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
    06:24

    Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

    Published on: January 10, 2025

    1.7K
  • Assessment of potential improvements in patient compliance.

    • Main Results:

    • Several long-acting rhGH formulations are in advanced research stages.
    • Reduced injection frequency is a key goal for improving adherence.
    • Sustained-release formulations offer a promising alternative to daily injections.

    Conclusions:

    • Long-acting rhGH formulations are being developed to address the limitations of daily injections.
    • These novel formulations have the potential to significantly improve treatment adherence and patient experience.
    • The development of sustained-release rhGH represents a significant advancement in pediatric endocrinology.